Company Filing History:
Years Active: 2015-2022
Title: Ulla Hansen: Innovator in Cancer Treatment
Introduction
Ulla Hansen is a prominent inventor based in Bedford, MA (US), known for her significant contributions to cancer treatment through innovative research. With a total of 9 patents, she has made remarkable strides in the field of oncology, particularly in developing inhibitors for cancer therapies.
Latest Patents
Among her latest patents, Ulla Hansen has developed Quinolin-2(1H)-one inhibitors of Late SV40 Factor. This invention focuses on compositions, methods, and kits for the treatment of cancer, specifically hepatocellular carcinoma (HCC). The invention discloses the use of small-molecule compounds to inhibit tubulin acetylation, which can inhibit cell migration and modulate cell compaction. Additionally, her work on Late SV40 (LSF) inhibitors also targets compositions, methods, and kits for treating HCC, utilizing small-molecule compounds to inhibit tubulin methylation and modulate chromatin or cytoskeleton modifications in cells.
Career Highlights
Ulla Hansen has had a distinguished career, working with reputable institutions such as Boston University and the Trustees of Boston University. Her research has been pivotal in advancing cancer treatment methodologies and enhancing the understanding of cellular mechanisms involved in cancer progression.
Collaborations
Ulla has collaborated with notable colleagues, including Scott Edward Schaus and Joshua A Bishop, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Ulla Hansen's work exemplifies the impact of innovative research in the medical field, particularly in cancer treatment. Her patents and collaborations highlight her commitment to advancing healthcare solutions.